Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer
10.3760/cma.j.cn112152-20200330-00276
- VernacularTitle:免疫检查点抑制剂在非小细胞肺癌临床诊疗中的研究进展
- Author:
Ying HUANG
1
;
Ke XU
;
Wei WANG
;
Fei CUI
;
Yuan ZENG
;
Zhexue HAO
;
Weipeng CAI
;
Jianxing HE
;
Jun LIU
Author Information
1. 呼吸疾病国家医学中心 广州呼吸健康研究院 广州医科大学附属第一医院胸外科 510000
- Keywords:
Neoplasms, non-small cell lung;
Immune checkpoint inhibitor;
Anti-PD-1 antibody;
Anti-PD-L1 antibody
- From:
Chinese Journal of Oncology
2020;42(9):713-717
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is currently the malignant tumor with the highest morbidity and mortality in the world, and the main type is non-small cell lung cancer. Immune checkpoint inhibitor is a landmark discovery in the history of cancer treatment, which rewrites the history of cancer treatment, and improves the medical treatment of advanced tumors by a big step forward. The article summarizes the research progress of therapeutic drugs against anti-programmed cell death protein and programmed cell death protein ligand antibodies in the clinical diagnosis and treatment of non-small cell lung cancer. The principle of drug action, the differences in the diagnosis and treatment of non-small cell lung cancer in different clinical stages, and future research directions are discussed to provide the usage guidelines of immune checkpoint inhibitors for clinical oncologists.
